

**H7 Hemagglutinin (HA) Protein from Influenza A Virus, A/Canada/rv444/2004 (H7N3), Recombinant from Baculovirus**

**Catalog No. NR-43740**

This reagent is the tangible property of the U.S. Government.

**For research use only. Not for use in humans.**

**Contributor:**

BEI Resources

**Manufacturer:**

Protein Sciences Corporation, Meriden, Connecticut, USA

**Product Description:**

A recombinant form of the H7 hemagglutinin (HA) protein from influenza A virus, A/Canada/rv444/2004 (H7N3) was produced in Sf9 insect cells using a baculovirus expression system. The full-length recombinant H7 HA protein was purified by ion exchange and hydrophobic interaction chromatography.<sup>1</sup>

**Material Provided:**

Each vial contains approximately 0.2 mL of purified recombinant HA protein in 10 mM sodium phosphate buffer, pH 7, containing 150 mM sodium chloride and 0.005% Tween 20. The concentration, expressed as mg per mL, is shown on the Certificate of Analysis.

**Packaging/Storage:**

Purified recombinant HA protein was packaged aseptically, in screw-capped plastic cryovials. This product is provided on blue ice and should be stored at 2°C to 8°C immediately upon arrival. Do not freeze.

**Functional Activity:**

NR-43740 shows hemagglutination (HA) activity with chicken red blood cells and is functional in HA inhibition assays, SDS-PAGE, western blot and ELISA.<sup>1</sup>

**Citation:**

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: H7 Hemagglutinin (HA) Protein from Influenza A Virus, A/Canada/rv444/2004 (H7N3), Recombinant from Baculovirus, NR-43740."

**Biosafety Level: 1**

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 6th ed. Washington, DC: U.S. Government Printing Office, 2020; see [www.cdc.gov/biosafety/publications/bmbl5/index.htm](http://www.cdc.gov/biosafety/publications/bmbl5/index.htm).

**Disclaimers:**

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at [www.beiresources.org](http://www.beiresources.org).

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

**Use Restrictions:**

**This material is distributed for internal research, non-commercial purposes only.** This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

**References:**

1. Govorkova, E. A., Personal Communication.
2. Hirst, M., et al. "Novel Avian Influenza H7N3 Strain Outbreak, British Columbia." *Emerg. Infect. Dis.* 10 (2004): 2192-2195. PubMed: 15663859.
3. Tweed, S. A., et al. "Human Illness from Avian Influenza H7N3, British Columbia" *Emerg. Infect. Dis.* 10 (2004): 2196-2199. PubMed: 15663860.
4. Pasick, J., et al. "Intersegmental Recombination between the Haemagglutinin and Matrix Genes was Responsible for the Emergence of a Highly Pathogenic H7N3 Avian Influenza Virus in British Columbia." *J. Gen. Virol.* 86 (2005): 727-731. PubMed: 15722533.

ATCC® is a trademark of the American Type Culture Collection.

